---
title: "AMOYTOP released its performance for the first half of the year, with a net profit attributable to the parent company of 428 million yuan, an increase of 40.60%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/253793733.md"
description: "AMOYTOP released its semi-annual report for 2025, with operating revenue of 1.511 billion yuan, a year-on-year increase of 26.96%; net profit attributable to the parent company was 428 million yuan, a year-on-year increase of 40.60%. The net profit after deducting non-recurring gains and losses was 431 million yuan, a year-on-year increase of 30.68%. The basic earnings per share were 1.05 yuan. The growth in performance was mainly attributed to the popularization of the clinical cure concept for hepatitis B and the increase in patients treated with the core product, Peginterferon"
datetime: "2025-08-20T10:48:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/253793733.md)
  - [en](https://longbridge.com/en/news/253793733.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/253793733.md)
---

# AMOYTOP released its performance for the first half of the year, with a net profit attributable to the parent company of 428 million yuan, an increase of 40.60%

According to the Zhitong Finance APP, AMOYTOP (688278.SH) released its semi-annual report for 2025, showing an operating income of 1.511 billion yuan, a year-on-year increase of 26.96%. The net profit attributable to shareholders of the listed company was 428 million yuan, a year-on-year increase of 40.60%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 431 million yuan, a year-on-year increase of 30.68%. The basic earnings per share were 1.05 yuan.

During the reporting period, the company's operating income increased by 26.96% year-on-year, mainly due to the continuous popularization of the concept of clinical cure for hepatitis B and the accumulation of scientific evidence, leading to a steady increase in the number of patients receiving treatment with the company's core product, Peginterferon

### Related Stocks

- [688278.CN](https://longbridge.com/en/quote/688278.CN.md)

## Related News & Research

- [BoE Gov. Bailey: We have a softening picture for growth and the labour market](https://longbridge.com/en/news/287076756.md)
- [CONSERVATIVE KEIKO FUJIMORI SEEN WINNING PERU'S PRESIDENTIAL RUNOFF AGAINST LEFTIST ROBERTO SANCHEZ- POLL](https://longbridge.com/en/news/287060008.md)
- [ZAWYA: Sahm App exceeds 2mln users, marking a new milestone in its growth journey](https://longbridge.com/en/news/287084031.md)
- [Chemtrade Logistics Holds Guidance Amid Commodity Swings](https://longbridge.com/en/news/286831060.md)
- [China's Bio-Thera Gets US Nod for Golimumab Biosimilar](https://longbridge.com/en/news/286880573.md)